von Willebrand Factor
Vonvendi is a recombinant von Willebrand factor (VWF) replacement therapy used to treat and control bleeding episodes in adults with von Willebrand disease (VWD), including the most common form (Type 1) as well as more severe types. It can also be used during surgery or other invasive procedures to help manage bleeding in these patients. This medication provides the missing clotting protein that patients with VWD lack, helping to restore normal blood clotting function.
Vonvendi is a recombinant von Willebrand factor replacement therapy for adults with von Willebrand disease to treat or prevent bleeding.
Key facts at a glance
- RxNorm
- 1812594
- Generic
- Vonvendi
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Vonvendi is indicated for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease. It is also used for perioperative management of surgical and/or invasive procedure-related bleeding in adults with VWD.
Vonvendi contains recombinant von Willebrand factor (rVWF), which replaces the deficient or defective VWF in patients with von Willebrand disease. VWF plays a critical role in blood clotting by facilitating platelet adhesion to injured blood vessel walls and by stabilizing factor VIII in the bloodstream.
Vonvendi is administered by intravenous infusion. It is a recombinant product (not derived from human plasma), which eliminates the risk of plasma-borne infections. Patients should be monitored for signs of allergic reactions or thrombotic events during treatment. Dosing is individualized based on the patient's weight, bleeding severity, and clinical response. Antihemophilic factor/factor VIII levels should be monitored, especially in patients requiring surgery.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy